Christopher Chu, MD
Allergy & Immunology · Boston, MANPI 1699271551
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.0%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 19 manufacturers reported payments, led by CSL Behring at 37.8% of the total. 2025 is the largest year on record at $14,433, more than ten times the $69 reported in 2021.
Across 239 payments — averaging $109.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- CSL Behring$10K
- Regeneron Healthcare Solutions, Inc.$5K
- AstraZeneca$5K
- AbbVie$1K
- Takeda Pharmaceuticals U.S.A., Inc.$990
- GSK$669
- plus $3K from 13 others
What the payments were for
- Consulting fees$14,16554%
- Travel & lodging$2,1678%
- Food & beverage$9,71737%
- Education$1881%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| CSL Behring | 22 | $9,929 |
| Regeneron Healthcare Solutions, Inc. | 18 | $5,229 |
| AstraZeneca | 70 | $4,584 |
| AbbVie | 14 | $1,391 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $990 |
| GSK | 19 | $669 |
| Amgen | 21 | $667 |
| Sanofi | 10 | $665 |
| Biocryst US Sales Co., LLC | 15 | $542 |
| Blueprint Medicines Corporation | 4 | $403 |
| Novartis | 9 | $361 |
| Pharming Healthcare, Inc. | 6 | $260 |
| Grifols USA, LLC | 8 | $157 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $146 |
| Incyte Corporation | 5 | $107 |
| Ionis Pharmaceuticals, Inc. | 2 | $63 |
| Kaleo, Inc. | 2 | $39 |
| Merck | 1 | $20 |
| Optinose US, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$26,238 in reported general payments places this provider in the 80th percentile of 114 allergy & immunology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 32 | $30,950 |
| Breo ElliptaFluticasone/Vilanterol | 16 | $8,334 |
| Arnuity ElliptaFluticasone Furoate | 19 | $6,693 |
| Epinephrine | 32 | $4,289 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $4,109 |
| Azelastine Hcl | 66 | $2,101 |
| Ipratropium Bromide | 44 | $1,753 |
| Fluticasone Propionate | 60 | $1,609 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 38 | $1,176 |
| Montelukast Sodium | 79 | $785 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Arnuity Ellipta | $669 | $45,97767 claims |
| AstraZenecaSymbicort | $4,584 | $4,10914 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 114 allergy & immunology providers in Massachusetts.
Other allergy & immunology in Boston
- Wanda PhipatanakulBoston$679K
- Kathleen BuchheitBoston$224K
- Aleena BanerjiBoston$133K
- Jeffrey GelfandBoston$84K
- Paul MaglioneBoston$66K
- Matthew GiannettiBoston$55K
- Aidan LongBoston$43K
- Wayne MarascoBoston$40K
- Michael PistinerBoston$36K
- Jocelyn FarmerBoston$32K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.